MedTrace Logo

Enoxaparin in Acute Venous Thromboembolic Disease

NCT00265993 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 251

Last updated 2010-02-03

No results posted yet for this study

Summary

Study objectives :

* To evaluate the efficacy/safety profile of enoxaparin once a day treatment in acute venous thromboembolic disease.

Conditions

  • Venous Thrombosis

Interventions

DRUG

enoxaparin

* All patients will be treated with enoxaparin 1.5 mg/kg, once a day, subcutaneously for up to 10 days. * Long-term oral anticoagulation will be started in all patients after 24 hours of initiation of enoxaparin treatment and continued at least for 3 months.

Sponsors & Collaborators

Principal Investigators

  • Edibe Taylan · Sanofi

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00265993 on ClinicalTrials.gov